SCHEDULE: Soleus Capital Discloses 7.6% Stake in Mural Oncology

Soleus Capital Master Fund and its affiliates have disclosed a 7.6% passive ownership stake in Mural Oncology PLC, holding 1,323,877 ordinary shares.

Summary

• Soleus Capital Master Fund, L.P., along with its affiliated entities Soleus Capital, LLC, Soleus Capital Group, LLC, Soleus Capital Management, L.P., Soleus GP, LLC, and individual Guy Levy, reported beneficial ownership of 1,323,877 ordinary shares of Mural Oncology PLC.
• This aggregate ownership represents 7.6% of Mural Oncology PLC's outstanding ordinary shares.
• The percentage is calculated based on 17,324,359 ordinary shares outstanding as of July 28, 2025, as reported in Mural Oncology's Form 10-Q for the fiscal quarter ended June 30, 2025.
• The reporting persons hold shared voting and shared dispositive power over all 1,323,877 shares.
• The filing indicates a passive investment, as the shares were not acquired or held for the purpose of changing or influencing the control of the issuer, nor in connection with any transaction having that purpose or effect, other than activities solely related to a nomination under Rule 14a-11.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While a 13G is a factual disclosure, the presence of a significant institutional investor holding a 7.6% stake can be viewed as a positive signal of confidence in the company, even if the investment is passive.

Positives

• A significant institutional investor, Soleus Capital Master Fund, L.P., and its affiliates, has taken a substantial 7.6% stake in Mural Oncology PLC, which can be interpreted as a vote of confidence in the company's long-term prospects.

Negatives

• The filing explicitly states that the shares were not acquired for the purpose of changing or influencing control, indicating a passive investment rather than an activist one that might push for strategic changes or improved governance.

Risks

• The reporting persons disclaim beneficial ownership of the shares held by Master Fund for any purpose other than determining their obligations under Section 13(d) of the Exchange Act, which limits their accountability for certain aspects of ownership.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding Mural Oncology PLC's future performance or strategic direction.

Industry Context

This filing is a standard disclosure of a significant passive ownership stake by an investment fund in a publicly traded company. It does not provide specific insights into broader industry trends or competitive landscape, beyond indicating an investment in the oncology sector.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional holder may influence investor perception and potentially provide a degree of stability or confidence in the stock.

Key Dates

Keywords

Mural Oncology PLC, Soleus Capital, Beneficial Ownership, SEC Filing, Schedule 13G, Institutional Investor, Ordinary Shares, Biotechnology, Oncology